Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Moodys
Daiichi Sankyo
Chubb
Cantor Fitzgerald
Mallinckrodt
Johnson and Johnson
Teva

Generated: April 25, 2018

DrugPatentWatch Database Preview

CEFTIN Drug Profile

« Back to Dashboard

When do Ceftin patents expire, and what generic alternatives are available?

Ceftin is a drug marketed by Glaxosmithkline and is included in two NDAs.

The generic ingredient in CEFTIN is cefuroxime axetil. There are sixty-one drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the cefuroxime axetil profile page.
Drug patent expirations by year for CEFTIN
Pharmacology for CEFTIN
Synonyms for CEFTIN
(6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furanyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-acetyloxyethyl ester
(6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid 1-(Acetyloxy)ethyl Ester
(RS)-1-Hydroxyethyl (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), 1-acetate 3-carbamate
1-acetoxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furyl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-acetyloxyethyl (6R,7R)-3-(aminocarbonyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyimino-ethanoyl]amino]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, 1-(acetyloxy)ethyl ester, (6R-(6alpha,7beta(Z)))-
544C076
64544-07-6
A834806
AC1O426M
AKOS015896220
Altacef
AN-38773
anti-Cefloxime axetil
AT-20730
Bioracef
BRN 6854419
C08107
C20H22N4O10S
CCG-221241
CCI 1564
CCI 15641
CCI-15641
Cefaks
Cefazine
Cefuroximaxetil
Cefuroxime 1-acetoxyethyl ester
cefuroxime axetil
Cefuroxime axetil (JP17/USP/INN)
Cefuroxime axetil [USAN:BAN:JAN]
Cefuroxime axetil [USAN:USP:BAN:JAN]
Cefuroxime Axetil, European Pharmacopoeia (EP) Reference Standard
Cefuroxime Axetil, mixture of isomers, analytical standard
Cefuroxime Axetil, United States Pharmacopeia (USP) Reference Standard
Celocid
Cepazine
Cethixim
Cetoxil
CHEBI:3516
CHEMBL1095930
Coliofossim
CXM-AX
D00914
DRG-0157
Elobact
Forcef
Furoxime
HSDB 8150
I06-1564
Kalcef
LS-149935
Maxitil
Medoxm
MolPort-005-935-571
Nivador
SCHEMBL721709
Sharox-500
SN 407
SN-407
ST51053128
Zinat
Zinnat
Zoref

US Patents and Regulatory Information for CEFTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline CEFTIN cefuroxime axetil FOR SUSPENSION;ORAL 050672-001 Jun 30, 1994 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline CEFTIN cefuroxime axetil TABLET;ORAL 050605-002 Dec 28, 1987 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline CEFTIN cefuroxime axetil FOR SUSPENSION;ORAL 050672-002 Apr 29, 1997 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline CEFTIN cefuroxime axetil TABLET;ORAL 050605-001 Dec 28, 1987 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Deloitte
Federal Trade Commission
US Department of Justice
Teva
Cerilliant
Moodys
Cantor Fitzgerald
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.